Related Experiment Videos
Danazol for unexplained infertilty
E Hughes1, G Tiffin, P Vandekerckhove
1Rm HSC-4F7, Department of Obstetrics and Gynaecology, McMaster University, 1200 Main St West, Hamilton, Ontario, Canada, L8N 3Z5. hughese@fhs.csu.mcmaster.ca
The Cochrane Database of Systematic Reviews
|May 5, 2000
Summary
Danazol, an androgen, was investigated for treating unexplained infertility. Current evidence is insufficient to determine its effect on pregnancy rates in women with unexplained subfertility.
Area of Science:
- Reproductive Endocrinology
- Clinical Trials
- Evidence-Based Medicine
Background:
- Danazol, an androgen, was developed in the 1970s for endometriosis treatment.
- Its application was later extended to women experiencing unexplained infertility.
- Two randomized trials were conducted to evaluate danazol's efficacy in this patient group.
Purpose of the Study:
- To assess the impact of danazol on pregnancy rates among women with unexplained subfertility.
- To synthesize evidence from randomized controlled trials regarding danazol's effectiveness.
Main Methods:
- A systematic search of the Cochrane Subfertility Review Group's specialized register of controlled trials was performed.
- Inclusion criteria focused on randomized trials comparing danazol with placebo or no treatment in women with unexplained subfertility.
- Data extraction was conducted independently by two reviewers.
Main Results:
- Two trials, involving a total of 68 women, were analyzed.
- No statistically significant difference in pregnancy rates was observed between the danazol and placebo groups (odds ratio 2.57, 95% confidence interval 0.53 to 12.46).
Conclusions:
- Insufficient evidence exists to conclusively evaluate danazol's effect on pregnancy rates in unexplained subfertility.
- Considerations such as the necessity of contraception during treatment, potential adverse effects, and cost implications warrant further attention.